Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 3:12:777-782.
doi: 10.2147/CMAR.S239647. eCollection 2020.

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC

Naoko Katsurada  1 , Motoko Tachihara  1 , Yukihisa Hatakeyama  1 , Kiyoko Koyama  1 , Masako Yumura  1 , Tatsunori Kiriu  1 , Ryota Dokuni  1 , Daisuke Hazama  1 , Shuntaro Tokunaga  1 , Daisuke Tamura  1 , Kyosuke Nakata  1 , Masatsugu Yamamoto  1 , Hiroshi Kamiryo  1 , Kazuyuki Kobayashi  1 , Yugo Tanaka  2 , Yoshimasa Maniwa  2 , Yoshihiro Nishimura  1
Affiliations
Case Reports

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC

Naoko Katsurada et al. Cancer Manag Res. .

Abstract

Purpose: Adjuvant chemotherapy with cisplatin (CDDP) plus vinorelbine is the standard regimen for the treatment of non-small cell lung cancer (NSCLC). However, CDDP elicits severe toxic effects, including emesis, neurotoxicity, and renal damage; carboplatin (CBDCA) may be a feasible alternative for CDDP-unfit patients. CBDCA plus paclitaxel (PTX) adjuvant chemotherapy showed a survival benefit for patients with stage IB tumors >4 cm in size, while CBDCA plus nanoparticle albumin-bound (nab)-PTX showed greater efficacy and lower neurotoxicity than CBDCA plus PTX in advanced NSCLC. Here, we investigated the feasibility of using CBDCA plus nab-PTX as adjuvant chemotherapy for NSCLC.

Patients and methods: Patients with completely resected stage II or III NSCLC, with an Eastern Cooperative Oncology Group performance status of 0-1 and adequate kidney function, received four cycles of postoperative adjuvant chemotherapy with CBDCA (AUC=5 mg/mL/min, on day 1) and nab-PTX (100 mg/m2, on days 1, 8, and 15) administered every 4 weeks within 8 weeks after surgery. The study was designed as a prospective, single-center, Phase II study. The primary endpoint was the completion rate of chemotherapy; secondary endpoints were two-year relapse-free survival (RFS) and safety. The expected completion rate was 80%, with a 50% lower limit.

Results: Of 21 enrolled patients, 18 (85.7%) were CDDP-unfit owing to age (≥75 years old [n=11, 52.4%]) or mild renal impairment (n=7, 33.3%). Nineteen of the 21 enrolled patients were assigned to the intervention. The most common grade 3 or 4 adverse events were neutropenia (n=15, 78.9%) and anemia (n=3, 15.8%). The completion rate for the four cycles was 63.2% (95% CI, 38.4-83.7). Two-year RFS was 56.8% (95% CI, 29.7-76.9).

Conclusion: The completion rate for CBDCA plus nab-PTX as adjuvant chemotherapy for CDDP-unfit NSCLC patients did not reach treatment feasibility. Further dose modifications may be required in future studies.

Keywords: adjuvant chemotherapy; carboplatin; nab-paclitaxel; non-small cell cancer.

PubMed Disclaimer

Conflict of interest statement

Dr Yoshihiro Nishimura reports grants from Taiho Pharmaceutical Co., Ltd, during the conduct of the study. The authors report no other conflicts of interest in this study.

Figures

Figure 1
Figure 1
CONSORT flow chart of the study.
Figure 2
Figure 2
Kaplan–Meier curve of recurrence-free survival (RFS) of patients receiving assigned intervention.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.v68.6 - DOI - PubMed
    1. Okami J, Shintani Y, Okumura M, et al.; For the Japanese Joint Committee of Lung Cancer Registry. Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese joint committee of lung cancer registry database in 2010. J Thorac Oncol. 2019;14(2):212–222. doi: 10.1016/j.jtho.2018.10.002 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al.; For the LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–3559. doi: 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol. 2010;5(2):220–228. doi: 10.1097/JTO.0b013e3181c814e7 - DOI - PubMed
    1. Cheong KA, Chrystal K, Harper PG. Management of the elderly patient with advanced non-small cell lung cancer. Int J Clin Pract. 2006;60(3):340–343. doi: 10.1111/ijcp.2006.60.issue-3 - DOI - PubMed

Publication types